New research suggests that fluorodeoxyglucose (FDG) PET is better for assessing the severity of Alzheimer’s disease and mild cognitive impairment (MCI) than florbetapir-PET scans.

A recent story in the New York Times analyzed the positives and potential negatives of undergoing an amyloid PET scan to gain insight into one’s risk of developing Alzheimer’s.

The American Society of Radiologic Technologists (ASRT) voiced their support for recent legislation that seeks to improve patient-access to radiopharmaceuticals in an Aug. 1 statement.

Researchers compared prostate-specific membrane antigen (PSMA) PET/CT to traditional 18F-fluciclovine PET/CT for the detection of biochemically recurrent prostate cancer.

A team of Japan-based researchers have created a medical camera capable of detecting and imaging radiotracers used in both PET and SPECT scans with limited radiation dosage.

An Australian Nuclear Science and Technology Organization (ANSTO) spokesman told the Australian the increase will be anywhere from 3-9%.

Increasing daily physical activity may help older adults delay their progression to Alzheimer’s disease (AD), according to research published July 16 in JAMA Neurology.  

The Department of Energy (DOE)’s National Nuclear Security Administration has awarded cooperative agreements for the production of molybdenum-99 (Mo-99) to three U.S. companies, including NorthStar Medical Radioisotopes.

“The differences that we observed indicate the strong possibility that there are sex differences in the structural and functional connections in the brain, which may contribute to women’s increased risk for Alzheimer’s,” said Sepideh Shokouhi, at the Alzheimer’s Association International Conference in Los Angeles.

Industry leaders, including the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Medical Imaging and Technology Alliance (MITA), hosted a Capitol Hill Briefing July 17, to discuss a bipartisan bill that would expand patient access to diagnostic radiopharmaceuticals.

NorthStar Medical Radioisotopes has finished construction of its new molybdenum-99 (Mo-99) processing facility in Beloit, Wisconsin, the company announced on July 16.

A novel PET radiotracer can help identify changes in the brain’s grey matter that may be indicative of progressive multiple sclerosis (MS), according to a pilot study published in the July issue of Neurology: Neuroimmunology & Neuroinflammation.